NKB2 Stoklara Genel Bakış Ticari aşamada bir biyofarmasötik şirketi olan TG Therapeutics, Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda B-hücresi aracılı hastalıklar için yeni tedavilerin satın alınması, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
TG Therapeutics, Inc. Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti TG Therapeutics Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$29.55 52 Haftanın En Yüksek Seviyesi US$34.17 52 Haftanın En Düşük Seviyesi US$12.08 Beta 2.26 1 Aylık Değişim 6.24% 3 Aylık Değişim -2.57% 1 Yıllık Değişim 129.60% 3 Yıllık Değişim 200.79% 5 Yıllık Değişim 100.20% Halka arzdan bu yana değişim 817.13%
Son Haberler & Güncellemeler TG Therapeutics, Inc. Provides Revenue Guidance for Fourth Quarter, Full Year of 2024 and Full Year 2025 Jan 15
CFO, Corporate Secretary & Treasurer recently sold €606k worth of stock Jan 09
Insufficient new directors Dec 30
Independent Director recently sold €448k worth of stock Nov 09
Third quarter 2024 earnings released: EPS: US$0.027 (vs US$0.80 in 3Q 2023) Nov 04
TG Therapeutics, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Nov 01 Daha fazla güncelleme görün TG Therapeutics, Inc. Provides Revenue Guidance for Fourth Quarter, Full Year of 2024 and Full Year 2025 Jan 15
CFO, Corporate Secretary & Treasurer recently sold €606k worth of stock Jan 09
Insufficient new directors Dec 30
Independent Director recently sold €448k worth of stock Nov 09
Third quarter 2024 earnings released: EPS: US$0.027 (vs US$0.80 in 3Q 2023) Nov 04
TG Therapeutics, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Nov 01
TG Therapeutics, Inc. Announces Updated Data Presentations Including New Five-Year Data from ULTIMATE I & II Phase 3 Trials Evaluating BRIUMVI (Ublituximab-Xiiy) in Patients with Relapsing Forms of Multiple Sclerosis Sep 18
Investor sentiment improves as stock rises 18% Aug 23
TG Therapeutics Receives U.S. Food and Drug Administration Clearance for Its Investigational New Drug (IND) Application Aug 09
Second quarter 2024 earnings released: EPS: US$0.048 (vs US$0.34 loss in 2Q 2023) Aug 07
Investor sentiment deteriorates as stock falls 17% Aug 05
TG Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Aug 05
Independent Director recently sold €404k worth of stock Jun 21
Los Angeles County Employees Retirement Association Files an Exempt Solicitation Statement with Securities and Exchange Commission Jun 14
CalSTRS Files an Exempt Solicitation Statement to Shareholders of TG Therapeutics Jun 13
Investor sentiment improves as stock rises 30% May 08
First quarter 2024 earnings released: US$0.073 loss per share (vs US$0.28 loss in 1Q 2023) May 02 TG Therapeutics, Inc. to Report Q1, 2024 Results on May 01, 2024
Lead Independent Director recently sold €322k worth of stock Mar 14
Full year 2023 earnings released: EPS: US$0.089 (vs US$1.47 loss in FY 2022) Feb 29
TG Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 05
Forecast breakeven date pushed back to 2024 Jan 12
CFO, Corporate Secretary & Treasurer recently sold €742k worth of stock Jan 08
Third quarter 2023 earnings released: EPS: US$0.80 (vs US$0.27 loss in 3Q 2022) Nov 03
TG Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 31
Forecast breakeven date pushed back to 2025 Oct 13
Chairman recently bought €924k worth of stock Aug 15
Second quarter 2023 earnings released: US$0.34 loss per share (vs US$0.30 loss in 2Q 2022) Aug 02
TG Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Aug 01
Independent Director recently sold €748k worth of stock Jun 27
Forecast breakeven date moved forward to 2024 Jun 26
CFO, Corporate Secretary & Treasurer recently sold €1.8m worth of stock Jun 06
Tg Therapeutics Announces European Commission Approval for Briumvi (Ublituximab-Xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults Jun 03
Tg Therapeutics Announces European Commission Approval for Briumvi (Ublituximab-Xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults Jun 02
First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.51 loss in 1Q 2022) May 02
Insufficient new directors May 01
No longer forecast to breakeven Mar 03
Full year 2022 earnings released: US$1.47 loss per share (vs US$2.63 loss in FY 2021) Mar 01
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum Feb 15
TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis Jan 28
Lead Independent Director recently sold €314k worth of stock Jan 08
Forecast to breakeven in 2025 Dec 31
TG Therapeutics, Inc. Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy) Dec 29
TG Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 09
Hagens Berman, National Trial Attorneys, Encourages TG Therapeutics Investors with Losses to Contact Firm’S Attorneys Before Sept. 16Th Deadline in Securities Fraud Class Action Sep 07
TG Therapeutics, Inc. Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Aug 26
Second quarter 2022 earnings released: US$0.29 loss per share (vs US$0.59 loss in 2Q 2021) Aug 09
Pomerantz Law Firm Announces the Filing of A Class Action Against TG Therapeutics, Inc Jul 19
TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS Jun 01
First quarter 2022 earnings released: US$0.51 loss per share (vs US$0.69 loss in 1Q 2021) May 11
TG Therapeutics, Inc., Annual General Meeting, Jun 16, 2022 May 02
TG Therapeutics, Inc. Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL Apr 16
TG Therapeutics, Inc. Announces Data Presentations from the Ultimate I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented At the American Academy of Neurology Annual Meeting Apr 05
TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLL Mar 06
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 02
TG Therapeutics, Inc. Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum Feb 26
TG Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 25 TG Therapeutics, Inc. Announces Data from the UNITY-CLL Phase 3 Trial Presented At the 63rd American Society of Hematology Annual Meeting
Third quarter 2021 earnings released: US$0.65 loss per share (vs US$0.73 loss in 3Q 2020) Nov 06
TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances Sep 24
TG Therapeutics, Inc. Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia Sep 21
Second quarter 2021 earnings released: US$0.59 loss per share (vs US$0.47 loss in 2Q 2020) Aug 03
No longer forecast to breakeven Aug 03 TG Therapeutics, Inc.(NasdaqCM:TGTX) dropped from Russell 3000E Value Index
TG Therapeutics, Inc. Announces Presentation of Data from the Ultimate I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis At 7th Congress of the European Academy of Neurology Jun 19
TG Therapeutics, Inc. Announces Data from Phase 1 Study Evaluating TG-1701 as a Monotherapy Jun 05
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma May 26
First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.48 loss in 1Q 2020) May 11
TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2B Trial Evaluating Umbralisib Mar 10
TG Therapeutics, Inc. to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the American Academy of Neurology 73rd Annual Meeting Mar 05
Revenue misses expectations Mar 02
Full year 2020 earnings released: US$2.42 loss per share (vs US$1.96 loss in FY 2019) Mar 02
TG Therapeutics, Inc. to Report Q4, 2020 Results on Mar 02, 2021 Feb 27
TG Therapeutics Announces Publication of Final Results from the Phase 3 Genuine Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in the Lancet Haematology Feb 24
TG Therapeutics, Inc. Announces FDA Accelerated Approval of UKONIQ™ (Umbralisib) Feb 06
New 90-day high: €45.80 Jan 14
TG Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $274.92 million. Dec 15
Independent Director recently sold €992k worth of stock Dec 12
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis Dec 12
New 90-day high: €33.34 Dec 11
TG Therapeutics Announces Publication of Phase 2 Data Evaluating Umbralisib in Patients with Chronic Lymphocytic Leukemia Who Are Intolerant to Prior BTK or PI3K Inhibitor Therapy in Blood Dec 03
TG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Approval of Ublituximab Investigational Glycoengineered Anti-CD20 Monoclonal Antibody Dec 02
Revenue beats expectations Nov 11
Third quarter 2020 earnings released: US$0.73 loss per share Nov 11
New 90-day high: €23.30 Oct 01
New 90-day high - €21.29 Sep 02
First half earnings released Aug 10
TG Therapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020 Aug 07
TG Therapeutics, Inc.(NasdaqCM:TGTX) dropped from Russell Microcap Growth Index Jul 04
TG Therapeutics, Inc.(NasdaqCM:TGTX) dropped from Russell Microcap Value Index Jul 02 Hissedar Getirileri NKB2 DE Biotechs DE Pazar 7D -4.9% 1.2% 2.3% 1Y 129.6% -5.6% 16.7%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: NKB2 geçen yıl % -5.6 oranında getiri sağlayan German Biotechs sektörünü aştı.
Getiri vs Piyasa: NKB2 geçen yıl % 16.7 oranında getiri sağlayan German Piyasasını aştı.
Fiyat Oynaklığı Is NKB2's price volatile compared to industry and market? NKB2 volatility NKB2 Average Weekly Movement 9.7% Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
İstikrarlı Hisse Senedi Fiyatı: NKB2 hisse senedi fiyatı, son 3 ayda German piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: NKB2 'nin haftalık oynaklığı ( 10% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.
Şirket Hakkında Ticari aşamada bir biyofarmasötik şirketi olan TG Therapeutics, Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda B-hücresi aracılı hastalıklar için yeni tedavilerin edinilmesi, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Klinik olarak izole sendrom, relapsing-remitting hastalık ve yetişkinlerde aktif sekonder progresif hastalık dahil olmak üzere relapsing multipl skleroz (RMS) formları olan yetişkin hastaların tedavisi için bir anti-CD20 monoklonal antikoru olan BRIUMVI'yi sunmaktadır. Şirketin geliştirme hattı, nükseden veya refrakter marjinal bölge lenfoması ve foliküler lenfoması olan yetişkin hastaların tedavisi için oral bir PI3K-delta inhibitörü olan Umbralisib; in vitro kinaz taramasında BTK'ya seçicilik sergileyen, oral olarak temin edilebilen ve kovalent bağlı bir Bruton tirozin kinaz (BTK) inhibitörü olan TG-1701 ve bispesifik bir CD47 ve CD19 antikoru olan TG-1801'den oluşmaktadır.
Daha fazla göster TG Therapeutics, Inc. Temel Bilgiler Özeti TG Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? NKB2 temel i̇stati̇sti̇kler Piyasa değeri €4.30b Kazançlar(TTM ) -€13.82m Gelir(TTM ) €254.75m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) NKB2 gelir tablosu (TTM ) Gelir US$264.79m Gelir Maliyeti US$30.94m Brüt Kâr US$233.85m Diğer Giderler US$248.21m Kazançlar -US$14.36m
Son Raporlanan Kazançlar
Sep 30, 2024
Hisse başına kazanç (EPS) -0.10 Brüt Marj 88.31% Net Kâr Marjı -5.42% Borç/Özkaynak Oranı 127.1%
NKB2 uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/02/12 00:57 Gün Sonu Hisse Fiyatı 2025/02/12 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin .
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github 'da mevcuttur.
Analist Kaynakları TG Therapeutics, Inc. 20 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Alec Stranahan BofA Global Research Jonathan Aschoff Brean Capital Mayank Mamtani B. Riley Securities, Inc.
Göster 17 daha fazla analist 
